C. B. H. W. Lamers

Erasmus MC Cancer Institute — Netherlands

Medicine · Health Sciences

70h-index20.0kcitations708works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Helicobacter pylori-related gastroenterology studies(129), Gastroesophageal reflux and treatments(109), Neuropeptides and Animal Physiology(79), Neuroendocrine Tumor Research Advances(71), Gastrointestinal motility and disorders(59)

Publications692 total

1085P Adoptive cell therapy with TCR gene-engineered T cells directed against MAGE-C2-positive melanoma: An ongoing phase I trial
Annals of Oncology·2024Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Data from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Data from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Data from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Data from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Supplementary Figure from Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
2023Open Access
Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer
Journal for ImmunoTherapy of Cancer·2020· 17 citedOpen Access
page 1 of 35Next →

Frequent Co-authors

Hein W. Verspaget(9), Jan W. Gratama(8), Cornelis F.M. Sier(8), Jan B.�M.�J. Jansen(7), W. van Duijn(7), Stefan Sleijfer(6), F J G M Kubben(6), Reno Debets(5), G. Stoter(5), R. L. H. Bolhuis(5), G Griffioen(5), Wim H.J. Kruit(4), Egbert Oosterwijk(4), R. A. van Hogezand(4), H. Goebell(3), H.P.M. Festen(3), S. G. M. Meuwissen(3), Lukas J.A.C. Hawinkels(3), Kim Zuidwijk(3), Lucio C. Rovati(3)